The Need For Clarification On Post-Market Requirements For Pediatric Medicines
This article was originally published in SRA
Geneviève Michaux explains why guidance is needed to interpret the post-marketing requirements for drugs under the EU Paediatric Regulation.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.